Zoetis Diagnostics
Veterinary diagnostics business of Zoetis Inc., which became independent from Pfizer in 2013. Provides VETSCAN point-of-care instruments and tests, reference laboratory services, and AI-powered diagnostic platforms including Imagyst for veterinary clinics.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-10-23. Score revised 2026-10-23: 42 → 39.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Zoetis became a standalone public company with its February 2013 IPO, and Pfizer completed the separation through an exchange offer in June 2013. Medicines and vaccines dominated the business; diagnostics was a small complementary line. The IPO retired about $2.5 billion of Pfizer commercial paper, and the new company showed few enshittification pressures.
Pershing Square disclosed a stake of about $1.5 billion in November 2014, and its William Doyle joined the board in February 2015. In May 2015 Zoetis announced an efficiency program to cut about 2,000 to 2,500 positions, exit ten manufacturing sites and drop about 5,000 SKUs. By the end of 2017 about 2,600 positions had been eliminated. The FDA cited misleading Sileo promotion in 2016, and Zoetis bought Nexvet, the owner of ranevetmab, in 2017.
The roughly $2 billion Abaxis acquisition made VETSCAN point-of-care instruments, with their consumables-heavy revenue, the core of Zoetis Diagnostics. Zoetis then bought Phoenix, ZNLabs and Ethos (2019-2020) to enter reference labs, launched Imagyst in 2020 and offered Freedom Flex instrument terms. Around 2019 it stopped developing ranevetmab, and Virbac complained to the EC in November 2020.
EC inspectors raided Zoetis's Belgian offices in October 2021, and in December the board authorized a $3.5 billion buyback. Zoetis bought Jurox (New Zealand cleared it only after Zoetis gave up its Antisedan distribution rights) and Basepaws. In June 2022 its CFO acknowledged bundling diagnostics with drugs where allowed. A 2023 FDA untitled letter criticized Librela efficacy claims made after the drug's US launch.
The EC opened its formal abuse-of-dominance investigation (AT.40734) in March 2024. Pressure on the parent company built up: an IRS tax proposal, a Librela class action, the FDA's December 2024 Dear Veterinarian letter and a 2025 untitled letter. Zoetis authorized a $6 billion buyback, repurchased $1.8 billion in 2024 and raised its dividend 16%. On the diagnostics side, it launched OptiCell and expanded Imagyst's AI capabilities.
In December 2025 Zoetis priced convertible notes, mostly to fund buybacks, and repurchased $1,159 million of stock in the first half of 2026. Over the same period US companion-animal sales fell, guidance was cut in August, and a cost and productivity program brought employee terminations. Diagnostics kept growing through the VPG and VitalRADS acquisitions and new AI features. In July 2026 a hospital sued over an alleged Imagyst misdiagnosis, alongside new shareholder suits.
Alternatives
Heska point-of-care diagnostics are now part of Antech following Mars's 2023 acquisition. Antech offers in-house blood analyzers, rapid tests, digital cytology and diagnostic imaging. Review current equipment and contract terms directly with the provider.
Reference laboratory network owned by Mars Inc., offering diagnostic testing for veterinary clinics. Antech describes its network as North America's largest. Part of Mars Petcare's veterinary health and diagnostics portfolio alongside VCA, Banfield and BluePearl.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (55 events)
Zoetis IPO raises $2.2 billion on NYSE
Zoetis, Pfizer's animal health division, sold 86.1 million shares at $26 each in its IPO, raising about $2.24 billion. Shares rose 19% to $31.01 in late-afternoon trading. It was the largest U.S. IPO since Facebook's $16 billion offering in May 2012.
Pfizer completes full spinoff of Zoetis
Pfizer completed the full separation of Zoetis on June 24, 2013, exchanging its remaining 80.2% interest (400.985 million Zoetis shares) for approximately 405.117 million Pfizer shares. Zoetis became a fully independent public company. Pfizer's filing separately documents that the 2013 IPO exchanged shares for retirement of approximately $2.5 billion of Pfizer commercial paper.
Bill Ackman acquires $1.5 billion Zoetis stake
In November 2014, Bill Ackman's Pershing Square disclosed an 8.5% stake worth approximately $1.5 billion in Zoetis, working with Sachem Head. Zoetis adopted a one-year shareholder rights plan late Friday after the disclosure. Later reporting attributed Ackman's private criticism of Zoetis's higher costs to anonymous sources cited by Bloomberg; specific operational demands had not been disclosed.
Pershing Square gains Zoetis board seat
Zoetis appointed William F. Doyle from Pershing Square to its board, expanding the board to ten members and giving the activist investor board representation. Fierce Pharma reported in June 2015 that Ackman was pushing behind the scenes for restructuring changes expected to save $300 million, and noted that the plans followed Doyle’s appointment.
Zoetis announces operational efficiency program
Zoetis announced an operational efficiency program to eliminate approximately 5,000 product SKUs and sell or exit ten manufacturing sites over the long term. It expected to reduce approximately 2,000 to 2,500 positions through divestitures, attrition and involuntary terminations, primarily over the next 18 months. The program targeted approximately $300 million in annual savings by 2017. The company projected a $200 million net operating-profit benefit in 2017.
Zoetis Florham Park WARN notice affects 165 workers
New Jersey's 2015 WARN archive lists a Zoetis notice for 165 workers in Florham Park, effective August 11, 2015.
FDA finds Sileo promotional materials misleading about thunderstorm use
The FDA said Zoetis and Orion's Sileo promotional materials left out that Sileo had not been evaluated for aversion behaviors to thunderstorms. The agency said this misbranded the product and asked Zoetis to stop distributing the materials.
Zoetis agrees to acquire Nexvet Biopharma for approximately $85 million
Zoetis agreed to acquire Nexvet Biopharma, an Irish biologic therapeutics company developing monoclonal antibodies for companion animals, for approximately $85 million ($6.72 per share, a 66% premium). Nexvet's pipeline included ranevetmab for canine osteoarthritis pain and frunevetmab for feline pain, both targeting nerve growth factor. Completion was expected in the second half of 2017.
Zoetis reports approximately 2,600 positions eliminated
Zoetis reported that about 2,600 positions had been eliminated by December 31, 2017, counting divestitures, under its efficiency initiatives. It said the comprehensive operational efficiency program was substantially complete, and that an expanded supply network strategy added 40 more planned position reductions.
Zoetis announces $2 billion Abaxis acquisition
Zoetis announced a definitive agreement to acquire Abaxis, a maker of veterinary point-of-care diagnostic instruments including the VetScan family, for $83 per share in cash (approximately $2 billion). Consumables accounted for approximately 78% of Abaxis's fiscal 2018 revenue.
FDA cites misleading Apoquel risk representations
The FDA's Center for Veterinary Medicine said Zoetis's Apoquel website made false or misleading representations about the product's risks and therefore misbranded Apoquel. The FDA asked Zoetis to stop distributing the promotional materials described in the letter.
Zoetis terminates ranevetmab development after two years
Around 2019, approximately two years after acquiring Nexvet Biopharma, Zoetis terminated the development of ranevetmab, a competing monoclonal antibody for canine osteoarthritis pain that targeted the same indication as Zoetis's own bedinvetmab (Librela). Zoetis subsequently refused to transfer ranevetmab to Virbac, the French company holding exclusive commercialization rights outside the US and Canada under a pre-existing 2014 license agreement.
Zoetis enters reference lab market with rapid acquisitions
Zoetis acquired Phoenix Central Laboratory in the Pacific Northwest on October 31, 2019, marking its entry into reference laboratory services. It announced the acquisition of ZNLabs on November 22, about three weeks later. ZNLabs operated a Louisville hub and laboratories in Boise, Chicago, Cincinnati, Dallas, New Orleans and Salt Lake City. The announcement described ZNLabs's friendly service and no-contract model. In a court brief filed May 17, 2024, Zoetis and Zoetis Reference Labs argued that acquiring and integrating the three labs was intended to let ZRL enter and compete in diagnostic laboratory pathology services.
Kristin Peck succeeds Alaix as Zoetis CEO
Kristin Peck became CEO on January 1, 2020, succeeding Juan Ramón Alaix. Previously Executive Vice President and Group President of U.S. Operations, Business Development and Strategy, she had been appointed to the board in October 2019.
Zoetis promotes Freedom Flex diagnostic instrument agreements with flexible terms
Zoetis advertised its Freedom Flex program for in-clinic diagnostic instruments as offering simple agreements, flexible terms and financial benefits. The ad contrasted the program with hidden penalties and restrictive contracts, and tied its benefits to purchases of Zoetis pharmaceutical, equine and diagnostic products.
Zoetis acquires Ethos Diagnostic Science reference labs
Zoetis announced its acquisition of Ethos Diagnostic Science, adding veterinary reference laboratory locations in Boston, Denver and San Diego. Following Phoenix Lab in October 2019 and ZNLabs in November 2019, this was its third reference-lab acquisition in about four months. The reference laboratory services complemented Zoetis's point-of-care instruments and consumables.
FDA approves Simparica Trio combination parasiticide
The FDA approved Simparica Trio (sarolaner, moxidectin and pyrantel), a once-monthly chewable combining protection against heartworm disease, fleas, ticks, roundworms and hookworms. Zoetis called it the first monthly all-in-one combination for these indications.
Zoetis launches Vetscan Imagyst AI diagnostics platform
Zoetis launched Vetscan Imagyst, an AI-powered multi-purpose diagnostics platform combining artificial intelligence with access to remote expert pathologists, in September 2020. Initially offering AI fecal testing, it added digital cytology in October 2021.
Virbac files antitrust complaint against Zoetis with EC
Virbac, the French animal health company that held exclusive commercialization rights to ranevetmab outside the US and Canada under a 2014 license agreement, filed a formal antitrust complaint with the European Commission. The complaint alleged that Zoetis abused its dominant position by terminating ranevetmab development and refusing to transfer the pipeline product to Virbac.
Librela receives EU marketing authorization
The European Commission granted Zoetis marketing authorization for Librela (bedinvetmab), the first injectable monoclonal antibody therapy approved in the EU for monthly alleviation of osteoarthritis pain in dogs.
Zoetis agrees to acquire animal health company Jurox
Zoetis announced an agreement to acquire Jurox, a privately held Australian animal health company that develops, manufactures and markets veterinary medicines for companion animals and livestock, including the anaesthetic Alfaxan.
EC conducts dawn raid on Zoetis Belgium offices
The European Commission conducted unannounced inspections at Zoetis's offices in Zaventem and Louvain-la-Neuve, Belgium, on October 25, 2021, as a preliminary investigation into suspected anticompetitive practices. The Commission emphasized that inspections did not establish guilt or prejudge the outcome.
Zoetis authorizes $3.5 billion share repurchase program
Zoetis's board authorized a multi-year share repurchase program of up to $3.5 billion. The program was completed by December 31, 2024. The company subsequently announced a larger $6 billion program while describing its capital allocation as both reinvestment in growth and shareholder returns.
FDA approves Solensia, first-ever animal monoclonal antibody
The FDA approved Solensia (frunevetmab injection), the first monoclonal antibody approved for use in any animal species, for control of osteoarthritis pain in cats. The product was developed from Nexvet's pipeline, alongside the terminated ranevetmab. Solensia expanded Zoetis's monoclonal antibody franchise and strengthened its competitive moat in pain management.
Zoetis CFO says the company bundles products where markets allow
At the Stifel Jaws & Paws conference, Zoetis CFO Wetteny Joseph said the company bundles products in markets where it can, and does not where it cannot. He said diagnostics plays a part in using Zoetis's portfolio to offer customers end-to-end solutions.
Zoetis acquires Basepaws pet genetics company
Zoetis completed the acquisition of Basepaws, a pet genetics company offering at-home DNA testing for cats with one of the world's largest feline genomic and oral microbiome databases. The acquisition expanded Zoetis into precision animal health, adding consumer genetic testing to its diagnostics portfolio and building a proprietary genomic data asset.
New Zealand clears Jurox deal after Zoetis gives up Antisedan distribution
New Zealand's Commerce Commission was concerned that buying Jurox would remove competition between the two companies in a market with only one other competitor. To address that, Zoetis surrendered its rights to distribute the antidote Antisedan in New Zealand, and the Commission then cleared the acquisition.
Industry guidance describes veterinary diagnostic contract risks
A dvm360 article describes industry contracts that may include exclusivity, minimum spending commitments, automatic renewals and default liabilities. Its hypothetical $36,000 annual commitment runs for five years even if $180,000 is spent earlier. On default, clinics may owe remaining commitments and repayment of discounts, rebates, equipment and cash incentives, with liabilities reaching tens or hundreds of thousands of dollars. The article does not identify these as Zoetis terms.
FDA approves Librela for US market after ranevetmab termination
The FDA approved Librela (bedinvetmab injection) for control of osteoarthritis pain in dogs, the first monoclonal antibody the FDA approved for use in dogs. With competing ranevetmab having been shelved by Zoetis, Librela entered the US market as the only available canine anti-NGF monoclonal antibody. Commercial launch followed in October 2023.
FDA issues untitled letter for misleading Librela promotions
The FDA's Center for Veterinary Medicine sent Zoetis an untitled letter finding that the Librela professional website made false or misleading efficacy claims, misbranding the product under the Federal Food, Drug and Cosmetic Act. Promotional graphs presented unadjusted statistical analysis of secondary endpoints without accounting for Type I error inflation, creating a misleading impression of efficacy beyond Day 28.
Zoetis and Techcyte introduce AI urine sediment analysis for Vetscan Imagyst
Zoetis and Techcyte introduced Vetscan Imagyst AI Urine Sediment Analysis, which brings in-house AI urine sediment testing to veterinary practices.
EC opens formal antitrust investigation into Zoetis
The European Commission launched a formal antitrust investigation (case AT.40734) into Zoetis for possible abuse of dominance under Article 102 TFEU. The investigation focuses on whether Zoetis acquired ranevetmab and then terminated it to eliminate competition for Librela, while refusing to transfer rights to Virbac. This is the EC's first-ever formal probe into post-acquisition shelving of a pipeline product encumbered by third-party rights.
IRS issues proposed adjustment for $450 million tax dispute
In July 2024, the IRS issued Notices of Proposed Adjustment related to Zoetis's 2018 mandatory deemed repatriation tax. A September 2024 Revenue Agent Report proposed approximately $450 million in additional tax liability, excluding interest and penalties. Zoetis protested on November 15, 2024, saying it disagreed with the IRS position. The amount was later disclosed in its filings; July 1 represents month precision.
Zoetis authorizes $6 billion share repurchase program
Zoetis's board authorized a multi-year $6 billion share repurchase program in August 2024. The previous $3.5 billion program was completed by December 31, 2024. Actual 2024 repurchases totaled $1.8 billion, excluding the excise-tax accrual.
Class action lawsuit filed over Librela adverse effects
A proposed class action lawsuit was filed against Zoetis in the U.S. District Court for the District of New Jersey, alleging Zoetis failed to adequately warn pet owners about dangers of Librela and misrepresented the treatment as safe. The suit cited thousands of adverse event reports including neurological injuries, seizures, urinary incontinence, and death. On July 22, 2026, the district court dismissed the Fourth Amended Complaint with prejudice.
Zoetis announces global launch of Vetscan OptiCell at VMX 2025
Zoetis announced that Vetscan OptiCell, the first cartridge-based AI-powered hematology analyzer for veterinary point-of-care, would launch at VMX 2025 in Orlando, January 25–29. The system uses proprietary single-use cartridges containing blood sample, reagents and waste, combined with viscoelastic focusing technology and AI algorithms counting hundreds of thousands of cells per run. Its cartridge model may increase switching costs, while AI-driven cell classification may make diagnostic decisions less transparent.
Zoetis raises quarterly dividend 16% for 2025
Zoetis declared a first-quarter 2025 dividend of $0.500 per share, 16% higher than its 2024 quarterly rate, payable March 4, 2025.
FDA issues Dear Veterinarian letter on Librela adverse events
The FDA issued a Dear Veterinarian letter notifying veterinarians about adverse events reported in dogs treated with Librela, including ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, polydipsia and death (including euthanasia).
FDA issues second untitled letter over misleading Zoetis drug promotions
The FDA issued an untitled letter to Zoetis after reviewing promotional videos on the Zoetis Petcare YouTube channel, finding false or misleading claims about risks associated with Librela, Solensia, and Revolution Plus. The videos showed before-and-after treatments without risk information, making efficacy claims without fair balance by hiding Important Safety Information behind expandable text.
FDA updates Librela label with client information and post-approval experience
The FDA's safety-labeling record shows that the Librela label now tells veterinarians to give dog owners a Client Information Sheet and discuss it with them. The label also gained a Post-Approval Experience subsection in its Adverse Reactions section.
Zoetis acquires Veterinary Pathology Group in the UK and Ireland
Veterinary Pathology Group (VPG), a veterinary diagnostic laboratory group with locations across the UK and Ireland, announced that it was now part of Zoetis. The deal extended Zoetis's reference-laboratory network into the UK and Ireland.
Zoetis prices $1.75 billion convertible-note offering to fund buybacks
Zoetis priced $1.75 billion in 0.25% convertible senior notes due 2029 and expected to use substantially all net proceeds for approximately $1.6 billion in share repurchases and capped-call transactions. The capped-call cap price of $211.715 per share represented a 75% premium to the December 15, 2025 share price.
Zoetis completes $2 billion convertible-note offering
Zoetis completed its private offering of 0.25% convertible senior notes due 2029. The $2.0 billion principal amount included $250 million issued after the initial purchasers exercised their option in full. Zoetis had said it would use most of the net proceeds for share repurchases and capped calls.
Zoetis lists a $55 monthly fee for low-spend reference-lab accounts
Zoetis's 2026 reference-laboratory Directory of Services lists a $55 monthly fee for customer accounts that spend $500 or less a month with Zoetis Reference Laboratories. Low-volume clinics pay this recurring charge.
Zoetis agrees to buy Neogen's global animal genomics business for $160 million
Neogen announced a definitive agreement to sell its global genomics business to Zoetis for $160 million, subject to customary closing adjustments, regulatory approval and closing conditions.
Zoetis adds CHCM to Vetscan OptiCell
Zoetis announced an expansion that makes Vetscan OptiCell the first point-of-care hematology analyzer to report cellular hemoglobin concentration mean (CHCM), a parameter the company said had previously been available only from reference labs.
Shareholder files securities class action over Zoetis product disclosures
A shareholder filed a proposed securities class action in the Southern District of New York (Case No. 1:26-cv-04401) against Zoetis and certain officers, covering purchasers from January 14, 2025 to May 6, 2026. It alleges misleading statements about the safety, competitive positioning and market share of companion-animal products including Librela, Simparica Trio, Apoquel and Cytopoint. Zoetis said it intends to defend the suit vigorously.
Shareholders file derivative actions against Zoetis officers and directors
Zoetis disclosed that several related shareholder derivative actions were filed in June 2026, naming the company as nominal defendant along with certain current and former officers and directors. They allege breach of fiduciary duty, unjust enrichment, waste, mismanagement and securities-law violations, based on facts similar to the May securities class action.
New Zealand regulator escalates review of Zoetis-Neogen genomics deal
After its initial investigation, the Commerce Commission decided to issue a Statement of Issues on Zoetis's proposed acquisition of Neogen's animal genomics business. The Commission said the statement would set out potential competition issues and was not a final decision on clearance.
Zoetis agrees to acquire veterinary teleradiology platform VitalRADS
Zoetis agreed to acquire VitalRADS, a veterinary teleradiology services platform, building on a partnership announced in August 2025. The deal adds round-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform to Zoetis's diagnostics portfolio.
Federal court dismisses Hartney Librela class action with prejudice
The US District Court for the District of New Jersey granted Zoetis's motion to dismiss the Fourth Amended Class Action Complaint in the Librela consumer case, with prejudice.
Oregon veterinary hospital sues Zoetis over alleged Vetscan Imagyst misdiagnosis
Columbia Veterinary Hospital sued Zoetis in Wasco County Court, Oregon, seeking at least $50,000 and alleging fraud and deceptive business practices. It says Vetscan Imagyst classified an 11-year-old dog's mass as an inflammatory lesion rather than cancer, which led to a second surgery before the dog died of post-operative complications. The complaint also alleges that Zoetis promoted Imagyst as 'the world's most capable veterinary AI analyzer' while omitting known limitations, and modified the initial report after staff reported the error. These are unadjudicated allegations.
Zoetis cuts 2026 guidance and books job-cut costs under a cost program
Zoetis cut its full-year 2026 revenue guidance to $9.120-$9.320 billion (organic operational growth of -3% to -1%), down from the $9.680-$9.960 billion it gave in May, as US companion-animal sales fell 11% in the quarter. Its second-quarter results included $75 million of restructuring and cost-reduction charges, mainly employee-termination costs under a comprehensive cost and productivity program. The company also said diagnostics was one of its areas of strength.
Zoetis adds blood-parasite detection to Vetscan Imagyst AI Blood Smear
Zoetis added blood-parasite detection, expanded cell classification and whole-slide scanning to the Vetscan Imagyst AI Blood Smear capability, to help veterinarians spot clinically important pathogens at the point of care.
FDA updates Solensia label with client information and post-approval safety data
The FDA's safety-labeling record shows that the Solensia label gained a Post-Approval Experience subsection and a Client Information Sheet for cat owners that emphasizes safety and risk information.
Evidence (67 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (6 entries)
42→39. Since Oct 2025: Zoetis sold $2.0B of convertible notes mostly to fund buybacks and repurchased $1,159M in H1 2026, while US companion-animal sales fell 11%, guidance was cut on Aug 6, 2026 and a cost and productivity program booked employee terminations. It acquired VPG and VitalRADS and agreed to buy Neogen genomics (NZ Statement of Issues). Shareholder securities and derivative suits were filed, the Hartney Librela suit was dismissed with prejudice, an Oregon hospital sued over an alleged Imagyst misdiagnosis, and new Imagyst/OptiCell features shipped. Dimensions: D1 4→3 (correction: fact audit showed industry contract risks and pharma Trustpilot complaints are not diagnostics findings; diagnostics features improving; offset by $55 low-volume lab fee and Imagyst lawsuit allegation). D2 5→3 (correction: exclusivity/quota/default terms are industry, not Zoetis; Zoetis-specific record is bundling where allowed, $55 low-spend fee, no-contract ZNLabs, Freedom Flex). D4 5→4 (correction: early-termination liabilities not Zoetis terms; consumables and PMS integration remain). D9 4→5 (event: 2026 cost-program employee terminations concurrent with $1,159M H1 buybacks). Others confirmed. Eras: 'Pfizer Spinoff' kept; 'Ackman Restructuring' re-dated 2015-06-01→2014-11-12 (Pershing stake); 'Acquisition Consolidation' re-dated 2018-07-01→2018-07-31 (Abaxis close) and relabeled 'Abaxis Diagnostics Buildout'; 'Diagnostics Expansion' re-dated 2023-06-01→2021-10-25 (EC dawn raid) and relabeled 'EC Raid, Buyback Ramp'; 'Regulatory Scrutiny' re-dated 2026-02-20→2024-03-26 (EC formal investigation); new 'Debt-Funded Buybacks' era from 2025-12-16 (convertible pricing for buybacks). All eras re-scored from criteria. Skipped candidates: Brazil environmental proceeding (procedural, unrelated), privacy notice (company-wide boilerplate), UK AI Masses launch (duplicate), CEO cash pay (covered), earnings/diagnostics-growth items without user effect, Jurox completion and NZ Neogen application (covered by adjacent events), equine features. Category Pet Care & Veterinary fits.
Checked 14 removed/trimmed candidates: 0 restored, 3 partly restored, 11 confirmed removed, 0 already present. PARTLY RESTORED timeline:update:2: dropped 8.5% restored from Reuters November 12, 2014; immediate poison pill and specific operational demands not restored. PARTLY RESTORED timeline:update:3: Fierce Pharma June 18, 2015 supports attributed activist pressure connected to the $300M plan after Doyle appointment, not proven board-seat causation. PARTLY RESTORED timeline:update:8: defendants’ May 17, 2024 court brief supports intended market entry/competition through three-lab integration; named-rival challenge and aggressive characterization not restored. Added evidence items carry these same PARTLY RESTORED verdicts and sources (Reuters; Fierce Pharma; Schulman document 119). CONFIRMED REMOVED timeline:remove:7: dvm360 $36,000 is hypothetical industry context, not January 2019 Zoetis adoption; no qualifying source for Zoetis exclusivity, 72/84 months or retained equipment ownership. CONFIRMED REMOVED timeline:update:23: Q2 2025 filing says July 2024 and 2018 mandatory repatriation tax; no July 24 precision or spinoff-era wrongdoing established. CONFIRMED REMOVED timeline:update:27: NJ WARN dates 165 Florham Park positions to 2015; original employee post is August 2015. Already retained individual workload complaints do not prove the dropped 2024 headquarters-layoff or company-wide causal overtime claim. CONFIRMED REMOVED evidence:update:14: original margin/markup page read via web open after empty live and failed archive; it discusses clinics’ retail prices, not Zoetis negotiation opacity, and is vendor educational material. CONFIRMED REMOVED evidence:update:15 and evidence:update:18: dvm360 and VBA describe reading behavior/legal wording, not deliberate concealment by Zoetis. CONFIRMED REMOVED evidence:update:26: Kalorama explicitly names numerous competitors and low entry barriers; no qualifying support for three-player oligopoly. CONFIRMED REMOVED evidence:update:0: December 2024 launch release says in minutes; Australian user manual specifies <6 minutes; secondary under-five reports cite a release that does not state that figure. CONFIRMED REMOVED evidence:update:27: current Glassdoor page read (3.7, 1,148); exact-number/origin/date-drift searches do not establish historical 3.9/1,521 snapshot. CONFIRMED REMOVED evidence:update:30: no historical overall benefits 4.1/5 snapshot established; unrelated sick-leave/location ratings not substituted. CONFIRMED REMOVED evidence:update:32: OpenSecrets blocked, archive unavailable; exact $235,469/235469, named-origin and 2022-2025 drift searches did not establish contributions total. Fetch failures alone were not treated as proof. VIN acquisition-competition pages were unreadable despite retries/archive/web-open; search snippets were not used as restoration evidence. All restored facts come from pages read this session; no removals or score changes.
Audited73 timeline/evidence/milestone items plus2 alternatives, all prose and identity. Preserved true miscited details through primary sources and separately sourced evidence. Strict invented detail: IPO first-day $35.01 contradicts contemporaneous CBS/AP $31.01 (https://www.cbsnews.com/news/shares-of-animal-health-company-zoetis-soar-in-ipo/). Unsupported details: January2019 Zoetis contract adoption; deliberate contract concealment; margin-pricing benefit in Zoetis negotiations; OptiCell under5minutes; historical Glassdoor3.9 rating,1521 count,4.1 benefits rating; $235,469 political contributions; Doyle appointment caused300M savings; undisclosed operational demands at Ackman disclosure; company-wide excessive-overtime consequence of layoffs; Heska comparative nonexclusive-contract superiority. Numeric date drift ($781M/$450M/3800) was corrected and preserved, not called invented. {'itemsChecked': 75, 'verified': 7, 'corrected': 26, 'resourced': 38, 'removed': 4, 'dateFixes': 3, 'proseFixes': 25, 'inventedDetails': 1, 'unsupportedDetails': 12}